Business Context and Reporting Period
This Form 6-K filing by Anchiano Therapeutics Ltd. (noted as Chemomab Therapeutics Ltd. in metadata) covers the month of November 2019. The report discloses a corporate governance change effective November 11, 2019, regarding the appointment of a new director to the Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and related party disclosures rather than financial performance.
Material Changes
- Board Appointment: Mr. Ofer Gonen was appointed to the Board of Directors effective November 11, 2019.
- Shareholder Relationship: Mr. Gonen is the Chief Executive Officer of Clal Biotechnology Industries Ltd. (CBI), a principal shareholder holding approximately 23.57% of the Company's outstanding shares.
- Independence Status: The Board concluded that Mr. Gonen is not an independent director under Israeli law, SEC Rule 10A-3, or Nasdaq listing rules due to his affiliation with CBI.
Outlook, Risks, and Related Parties
Management Commentary and Risks: The filing details the ownership structure of CBI, tracing control back to Len Blavatnik and Access Industries. It notes that CBI and its affiliates beneficially owned 42.7% of the Company's securities as of April 24, 2019. The Company has an information rights agreement with CBI requiring the sharing of financial statements and material information.
Related Party Transactions: The report discloses that other Board members have affiliations with CBI or Elicio Therapeutics (a company in which CBI is a substantial shareholder). Specifically, Isaac Kohlberg serves on the CBI board, and former Board member Robert Connelly served as a Business Development Advisor to CBI. Dr. Frank Haluska, the Company's CEO, previously served on the board of Elicio Therapeutics.
Investor Verification Checklist
- Verify the current beneficial ownership percentage of CBI and its affiliates in Anchiano Therapeutics Ltd.
- Review the Company's Annual Report on Form 20-F for details on other related-party transactions with CBI.
- Confirm the status of the information rights agreement between the Company and CBI.
- Assess the impact of Mr. Gonen's appointment on the composition of independent directors on the Board.